HCV: the best cure possible or the best possible cure?

被引：5

作者：

Craxi, L. ^{[1
]}

Camma, C. ^{[2
]}

Craxi, A. ^{[2
]}

机构：

[1] Univ Cattolica Sacro Cuore, A Gemelli Sch Med, Inst Bioeth, Rome, Italy

[2] Univ Palermo, DiBiMIS, Sez Gastroenterol & Epatol, Palermo, Italy

来源：

JOURNAL OF VIRAL HEPATITIS | 2015年 / 22卷 / 08期

关键词：

Ethics; Direct acting antivirals; Hepatitis C virus; HEPATITIS-C; TRIPLE THERAPY;

D O I：

10.1111/jvh.12411

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Progress in medicine goes along with an exponential growth of the cost of drugs and devices. While any person has the right to obtain the best possible benefit from medical care, a state needs to strike a balance between granting the optimal personal benefit to each individual and the needs of the society as a whole. Health systems in all countries therefore are facing a huge problem of distributive justice, as while they should guarantee individual rights, among which the right to health in its broader sense, including physical, psychological and social well-being (therefore not limited to healing, but extending to compliance and quality of life), they must also grant equal access to the healthcare resources and keep the distribution system sustainable.

引用

页码：627 / 629

页数：3

共 11 条

[1] Identification of naive HCV-1 patients with chronic hepatitis who may benefit from dual therapy with peg-interferon and ribavirin [J].

Andriulli, Angelo ;

Di Marco, Vito ;

Margaglione, Maurizio ;

Ippolito, Antonio Massimo ;

Fattovich, Giovanna ;

Smedile, Antonina ;

Valvano, Maria Rosa ;

Calvaruso, Vincenza ;

Gioffreda, Domenica ;

Milella, Michele ;

Morisco, Filomena ;

Felder, Martina ;

Brancaccio, Giuseppina ;

Fasano, Massimo ;

Gatti, Pietro ;

Tundo, Paolo ;

Barone, Michele ;

Cozzolongo, Raffaele ;

Angelico, Mario ;

D'Andrea, Giovanna ;

Andriulli, Nicola ;

Abate, Maria Lorena ;

Mazzella, Giuseppe ;

Gaeta, Giovanni Battista ;

Craxi, Antonio ;

Santantonio, Teresa .

JOURNAL OF HEPATOLOGY, 2014, 60 (01) :16-21

[2] Informed Deferral: A Moral Requirement for Entry Into the Hepatitis C Virus Treatment Warehouse [J].

Aronsohn, Andrew ;

Jensen, Donald .

HEPATOLOGY, 2012, 56 (05) :1591-1592

[3] Costs of Telaprevir-Based Triple Therapy for Hepatitis C: $189,000 Per Sustained Virological Response [J].

Bichoupan, Kian ;

Martel-Laferriere, Valerie ;

Sachs, David ;

Ng, Michel ;

Schonfeld, Emily A. ;

Pappas, Alexis ;

Crismale, James ;

Stivala, Alicia ;

Khaitova, Viktoriya ;

Gardenier, Donald ;

Linderman, Michael ;

Perumalswami, Ponni V. ;

Schiano, Thomas D. ;

Odin, Joseph A. ;

Liu, Lawrence ;

Moskowitz, Alan J. ;

Dieterich, Douglas T. ;

Branch, Andrea D. .

HEPATOLOGY, 2014, 60 (04) :1187-1195

[4] Personalized Medicine vs Guideline-Based Medicine [J].

Goldberger, Jeffrey J. ;

Buxton, Alfred E. .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2013, 309 (24) :2559-2560

[5] Individualized Cost-Effectiveness Analysis [J].

Ioannidis, John P. A. ;

Garber, Alan M. .

PLOS MEDICINE, 2011, 8 (07)

[6] Hepatitis C drug affordability [J].

Kamal-Yanni, Mohga .

LANCET GLOBAL HEALTH, 2015, 3 (02) :E73-E74

[7] Personalized cost-effectiveness of boceprevir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C [J].

Petta, Salvatore ;

Cabibbo, Giuseppe ;

Enea, Marco ;

Macaluso, Fabio Salvatore ;

Plaia, Antonella ;

Bruno, Raffaele ;

Gasbarrini, Antonio ;

Bruno, Savino ;

Craxi, Antonio ;

Camma, Calogero .

DIGESTIVE AND LIVER DISEASE, 2014, 46 (10) :936-942

[8] Clinical impact of treatment timing for chronic hepatitis Cinfection: a decision model [J].

Pho, M. T. ;

Jensen, D. M. ;

Meltzer, D. O. ;

Kim, A. Y. ;

Linas, B. P. .

JOURNAL OF VIRAL HEPATITIS, 2015, 22 (08) :630-638

[9] Sticker Shock and the Price of New Therapies for Hepatitis C: Is It Worth It? [J].

Reau, Nancy S. ;

Jensen, Donald M. .

HEPATOLOGY, 2014, 59 (04) :1246-1249

[10] Revolution in hepatitis C antiviral therapy [J].

Sadler, Matthew D. ;

Lee, Samuel S. .

BRITISH MEDICAL BULLETIN, 2015, 113 (01) :31-44

← 1 2 →